Literature DB >> 8810630

National Asthma Education and Prevention Program working group report on the cost effectiveness of asthma care.

S Sullivan1, A Elixhauser, A S Buist, B R Luce, J Eisenberg, K B Weiss.   

Abstract

The cost effectiveness of asthma care is the first topic of the National Asthma Education and Prevention Program Task Force Report on the Cost Effectiveness, Quality of Care, and Financing of Asthma Care. This working group characterized the role of health economics in understanding optimal asthma management strategies. The report first reviews methods for economic evaluation of medical technologies, with a particular focus on cost-effectiveness analysis. Next, the report explores the nature and usefulness of several key asthma outcome measures, including clinical and symptom measures, measures of lung function, measures of functional status, and measures of health services utilization and cost. The working group also conducted a review of the literature on cost effectiveness of asthma patient education programs, pharmaceutical therapy, and a variety of alternative and adjunct interventions. The report concludes with recommendations for a standardized approach for economic evaluation study designs (e.g., common asthma outcomes, long-term follow-up, and studies with patients of different ages, socioeconomic statuses, and severity levels) and for an expansion in the number of such standardized asthma studies and cost-effectiveness analyses.

Entities:  

Mesh:

Year:  1996        PMID: 8810630     DOI: 10.1164/ajrccm/154.3_Pt_2.S84

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  13 in total

1.  Asthma outcome measures.

Authors:  K D Watkins
Journal:  J Med Syst       Date:  1999-08       Impact factor: 4.460

2.  Internal consistency, reproducibility, responsiveness, and construct validity of the Chinese (HK) version of the asthma quality of life questionnaire.

Authors:  M Chan-Yeung; B Law; S Y Sheung; C L Lam
Journal:  Qual Life Res       Date:  2001       Impact factor: 4.147

Review 3.  Regular treatment with long acting beta agonists versus daily regular treatment with short acting beta agonists in adults and children with stable asthma.

Authors:  E H Walters; J A Walters; P W Gibson
Journal:  Cochrane Database Syst Rev       Date:  2002

4.  Surveillance for isocyanate asthma: a model based cost effectiveness analysis.

Authors:  D M Wild; C A Redlich; A D Paltiel
Journal:  Occup Environ Med       Date:  2005-11       Impact factor: 4.402

Review 5.  Inhaled fluticasone propionate. A pharmacoeconomic review of its use in the management of asthma.

Authors:  H M Lamb; C R Culy; D Faulds
Journal:  Pharmacoeconomics       Date:  2000-11       Impact factor: 4.981

Review 6.  Asthma outcomes: healthcare utilization and costs.

Authors:  Lara J Akinbami; Sean D Sullivan; Jonathan D Campbell; Robert W Grundmeier; Tina V Hartert; Todd A Lee; Robert A Smith
Journal:  J Allergy Clin Immunol       Date:  2012-03       Impact factor: 10.793

Review 7.  Inhaled salmeterol/fluticasone propionate combination. A pharmacoeconomic review of its use in the management of asthma.

Authors:  A Markham; J C Adkins
Journal:  Pharmacoeconomics       Date:  2000-12       Impact factor: 4.981

8.  Cost effectiveness of fluticasone propionate and flunisolide in the treatment of corticosteroid-naive patients with moderate asthma.

Authors:  T Volmer; A Kielhorn; H H Weber; K J Wiessmann
Journal:  Pharmacoeconomics       Date:  1999-11       Impact factor: 4.981

9.  Cost effectiveness of fluticasone and budesonide in patients with moderate asthma.

Authors:  K O Steinmetz; T Volmer; M Trautmann; A Kielhorn
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

10.  The role of caregivers' depressive symptoms and asthma beliefs on asthma outcomes among low-income Puerto Rican children.

Authors:  Karen G Martínez; Edna Acosta Pérez; Rafael Ramírez; Glorisa Canino; Cynthia Rand
Journal:  J Asthma       Date:  2009-03       Impact factor: 2.515

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.